

Press release

Biotalys to Appoint Toni Bucci to its Board of Directors

Seasoned Agriculture and Biotech Executive With a Passion to Feed the World Sustainably

Ghent, BELGIUM – 25 March 2025, 07:00 CET – <u>Biotalys (Euronext: BTLS</u>), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, is pleased to announce the proposal to appoint Toni Bucci as independent director to its Board of Directors. Ms Bucci's appointment will become effective immediately upon election at the upcoming Biotalys shareholders' meeting on 22 April 2025. She will succeed Markus Heldt, who will retire from the Board.

Simon Moroney, Chairman of the Board at Biotalys, commented: "We are delighted to welcome Toni Bucci to our Board of Directors. Her extensive experience in agriculture and strategic leadership will be most welcome as we continue to build Biotalys into a leader in the future of sustainable crop protection. I would also like to extend my gratitude to Markus Heldt, who will retire from the board, for his dedication, guidance, and instrumental contributions during his tenure at the company. Markus's contributions have been invaluable, and we wish him all the very best for the future."

Kevin Helash, CEO of Biotalys, noted: "Toni is a highly respected leader, and we are thrilled to have her on board. Her deep industry expertise, passion for innovation, and experience in biotechnology and fermentation align perfectly with Biotalys' mission to transform crop protection with our proteinbased biocontrols. Her insights into AgTech's challenges and opportunities will be instrumental in driving our growth and advancing our novel solutions. We look forward to working closely with her to accelerate our impact in sustainable agriculture."

Dr Bucci has more than 30 years of experience, including leading and scaling agricultural and biotechnology companies, guiding their strategic growth and helping them navigate the route to commercialisation. Prior to her current focus leading start-ups, she spent 23 years at BASF where she was responsible for the research, development and commercialisation of new fungicides and insecticides as well as business development. She currently serves as an independent board director and advisor to several emerging biotech companies, with a strong focus on driving innovation and advancing sustainable agricultural solutions.

Toni Bucci said: "I am honoured to have this opportunity to join the Board of Biotalys and to contribute to the company's pioneering role in advancing sustainable and innovative solutions for agriculture. Biotalys is at the forefront of an exciting transformation in crop protection, and I look forward to working with the team to support its vision of building a healthier and more sustainable future for global food production."

Dr Bucci earned a PhD in Entomology from North Carolina State University, a Master's degree also in Entomology from the University of Georgia and a Bachelor of Science in Biology and Chemistry from Augusta State University.



About Biotalys

Biotalys is an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for the protection of crops and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on <u>www.biotalys.com</u>.



For further information, please contact:

Toon Musschoot, Head of IR & Communication T: +32 (0)9 274 54 00 E: <u>IR@biotalys.com</u>

Important Notice

Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the <u>annual report</u> on the consolidated annual accounts published on the <u>company's website</u>.

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'aim', 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys' actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.